Otsuka and Sino Biopharmaceutical side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Otsuka | Sino Biopharmaceutical |
|---|---|---|
| Phase 1 | Otsuka: 12 of its 25 programs at phase 1
and 7 more — sign in to see them all | Sino Biopharmaceutical: 37 of its 97 programs at phase 1
and 32 more — sign in to see them all |
| Phase 2 | Otsuka: 2 of its 25 programs at phase 2
| Sino Biopharmaceutical: 31 of its 97 programs at phase 2
and 26 more — sign in to see them all |
| Phase 3 | Otsuka: 10 of its 25 programs at phase 3
and 5 more — sign in to see them all | Sino Biopharmaceutical: 26 of its 97 programs at phase 3
and 21 more — sign in to see them all |
| Approved, new studies | Otsuka: 1 of its 25 programs at approved, new studies
| Sino Biopharmaceutical: 3 of its 97 programs at approved, new studies
|
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Otsuka8 readouts · 3 phase 3 | · | Otsuka, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3
| · | Otsuka, Feb ’27: 1 program whose next study reaches primary completion
| Otsuka, Mar ’27: 1 program whose next study reaches primary completion
| · | Otsuka, May ’27: 2 programs whose next study reaches primary completion, 2 in phase 3
| Otsuka, Jun ’27: 1 program whose next study reaches primary completion
| · | Otsuka, Aug ’27: 1 program whose next study reaches primary completion | · | · |
| Sino Biopharmaceutical37 readouts · 10 phase 3 | Sino Biopharmaceutical, Nov ’26: 4 programs whose next study reaches primary completion, 1 in phase 3
| Sino Biopharmaceutical, Dec ’26: 14 programs whose next study reaches primary completion, 4 in phase 3
and 9 more — sign in to see them all | Sino Biopharmaceutical, Jan ’27: 2 programs whose next study reaches primary completion, 2 in phase 3
| Sino Biopharmaceutical, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3
| Sino Biopharmaceutical, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3
| Sino Biopharmaceutical, Apr ’27: 2 programs whose next study reaches primary completion
| Sino Biopharmaceutical, May ’27: 1 program whose next study reaches primary completion
| · | Sino Biopharmaceutical, Jul ’27: 2 programs whose next study reaches primary completion
| Sino Biopharmaceutical, Aug ’27: 5 programs whose next study reaches primary completion, 1 in phase 3
| · | Sino Biopharmaceutical, Oct ’27: 2 programs whose next study reaches primary completion
|
Changed in the last 90 days
Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Otsuka
New programs 0
None
Reached a new phase 1
- VIS954phase 2 · Oct 23 · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Study stopped 1
- SEP-380135phase 1 · withdrawn Nov 19 · none of its studies left running“The trial was withdrawn prior to participant enrollment.” · NCT07455084
Primary completion later 3
- quabodepistatphase 3 · May 2027 → Sep 2028 (+16 mo) · moved Oct 26 · NCT07209761
- Tolvaptanphase 3 · Jul 2028 → Dec 2028 (+5 mo) · moved Oct 23 · NCT04782258
- SEP-380135phase 1 · Apr 2026 → Dec 2026 (+8 mo) · moved Oct 16 · NCT07455084
Sino Biopharmaceutical
New programs 3
- NTQ6179phase 1 · first study · Oct 20 · Acromegaly
- KYLO-0603phase 2 · first study · Sep 24 · Non-alcoholic Fatty Liver Disease
- TQF6422phase 1 · first study · Aug 26 · Obesity
Reached a new phase 1
- TQA3605phase 3 · Aug 28 · Hepatitis B, Chronic
Study stopped 0
None
Primary completion later 4
- TRD205phase 2 · Jun 2026 → Dec 2026 (+6 mo) · moved Nov 18 · NCT07543796
- benmelstobartphase 2 · Nov 2027 → Dec 2028 (+13 mo) · moved Nov 16 · NCT07548177
- catequentinib hydrochloridephase 2 · Nov 2027 → Dec 2028 (+13 mo) · moved Nov 16 · NCT07548177
- tecotabart vedotinphase 2 · Jul 2026 → Aug 2031 (+61 mo) · moved Oct 19 · NCT05934331
Where they overlap
Conditions where at least two of them have programs: 11 in all. A program counts in each condition its studies name most.
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
| Target | Otsuka | Sino Biopharmaceutical |
|---|---|---|
| EGFR | zipalertinibrule | FHND-9041, TQB2922, TQB6411, TQB3002 |
| PDCD1 | zimberelimabrule | Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868, TQB2252, penpulimabrule, tislelizumabrule |
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
- Programs a company names but has not registered are counted apart (Sino Biopharmaceutical: 19).